Neoleukin Therapeutics, Inc. (NASDAQ:NLTX – Get Free Report) rose 1.5% during mid-day trading on Monday . The stock traded as high as $23.80 and last traded at $23.23. Approximately 193,336 shares changed hands during mid-day trading, an increase of 286% from the average daily volume of 50,104 shares. The stock had previously closed at $22.89.
Neoleukin Therapeutics Price Performance
The firm has a 50-day simple moving average of $30.98 and a 200 day simple moving average of $37.15. The company has a market capitalization of $218.32 million, a PE ratio of -7.47 and a beta of 1.11.
Neoleukin Therapeutics Company Profile
Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.
Recommended Stories
- Five stocks we like better than Neoleukin Therapeutics
- How to Use the MarketBeat Dividend Calculator
- Build-Your-Bowl Battle: CAVA, Chipotle, and Sweetgreen Face Off
- Investing in Travel Stocks Benefits
- Insiders Are Loading Up: 3 Key Stock Picks for Investors
- 3 Ways To Invest In Coffee, Other Than Drinking It
- How Cigna Remains at the Top of the Health Insurance Food Chain
Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
